Leslie Eiland, MD, discusses the benefits of remote monitoring among patients with type 1 diabetes (T1D) living in rural America.
Support of a local diabetes educator is important when it comes to improving health for rural patients with type 1 diabetes, said Leslie Eiland, MD, an endocrinologist at the University of Nebraska Medical Center in Omaha, Nebraska. Eiland's talk, "Use of Diabetes Technologies for Remote Monitoring in Ambulatory/Rural Settings," was presented at the American Diabetes Association's 81st Scientific Sessions.
Transcript:
Can you tell us a little bit about your work?
My name is Leslie Eiland. I'm an endocrinologist at the University of Nebraska Medical Center in Omaha, Nebraska. I am also the medical director of the endocrine telehealth program and the physician champion for telehealth at Nebraska Medicine.
How did you carry out your research on use of diabetes technologies for remote monitoring in ambulatory/rural settings?
Back in 2013, our division started our endocrine telehealth program, meaning we set up a telehealth site at a rural community hospital in central Nebraska and since then have expanded to 9 locations. Prior to COVID-19, if you wanted to do telehealth or video visits, it had to be done in a rural area, which is not that hard in Nebraska and Iowa where I practice—it's most of the geography—and it had to be done at a place of service. Patients had to travel to a rural hospital or clinic in order to see me over screen. Our clinics are anywhere from an hour-and-a-half to 8 hours from Omaha. When we started this clinic, or we started this program, and now have 9 sites, that's how we were caring for people with diabetes and other general endocrine issues for the last 8 years.
But then, with the public health emergency being declared around the time of COVID-19, that changed a lot of things in that you no longer had to have a patient in a rural area to have a telehealth visit. It could be anywhere, urban or rural. Home was recognized as a place of service. So people no longer had to travel to those visits in order for the visit to be an official visit or reimbursable. People could log in from home like many of us have been doing. There were a lot of changes. My research prior to COVID-19 has looked at type 1 diabetes (T1D) and how effective these telehealth clinics are in managing T1D.
What were the main findings of this research?
We feel that, based on our findings, for people who were seen in our clinics over the last 8 years for at least 3 visits with T1D, their glycated hemoglobin (A1Cs) have declined steadily over time. That's been independent or irrespective of whether they were previously seen by their primary care provider, a private endocrinologist, an academic endocrinologist, across the board. People's A1Cs slowly declined over time and the decline was consistent. The longer they were seen in our clinics the longer, or the greater, A1C decline they had. We think that some of that may be due to, because again, all these people were being seen at rural community hospitals, not home visits. We do think there's something important that happens there, in that they get the support of a local diabetes educator.
Almost all of our sites have a local certified diabetes educator there facilitating the visit, being available for interim education. I think the combination of the academic specialist with the local certified diabetes educator, and a certified diabetes care and education specialist who understands the more specific aspects of their local community really leads to good care for people with T1D.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More